A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines. - Wikidata - wikimedia - TriplyDB

A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines.

A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines.

http://www.wikidata.org/entity/Q33692070

about

Chimeric antigen receptor T-cell therapies for lymphoma.Chimeric Antigen Receptor T Cell Therapy: Challenges to Bench-to-Bedside Efficacy.Chimeric antigen receptor-T cell therapy for solid tumors require new clinical regimens.New Chimeric Antigen Receptor Design for Solid Tumors.Chimeric antigen receptor T‑cell therapy—a hematological success story.CAR-T Cells Based on Novel BCMA Monoclonal Antibody Block Multiple Myeloma Cell Growth The potential of CAR T therapy for relapsed or refractory pediatric and young adult B-cell ALL

P2860

Q38600697-F61FD198-E5BD-4DED-AA83-DC4615AAF69B Q47193084-4F56781D-CF7B-4814-8A8A-AA987DBF2AAA Q47629566-94114BF9-F473-4717-8185-FCC282E948C6 Q49711158-4CE7AB95-813E-445E-B03A-5AC1B13B749A Q55443158-F3452C91-197B-4F97-9536-DD1946083519 Q57158297-C670A459-FA49-41C2-B21E-ED4EE90A4E27 Q58767159-672EB879-F518-4222-BB0D-D46512FDEA1D

P2860

A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines.

http://www.wikidata.org/entity/Q33692070

description

2017 nî lūn-bûn

@nan

2017 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2017 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

name

A tandem CD19/CD20 CAR lentivi ...... lation in leukemia cell lines.

@ast

A tandem CD19/CD20 CAR lentivi ...... lation in leukemia cell lines.

@en

type

label

A tandem CD19/CD20 CAR lentivi ...... lation in leukemia cell lines.

@ast

A tandem CD19/CD20 CAR lentivi ...... lation in leukemia cell lines.

@en

prefLabel

A tandem CD19/CD20 CAR lentivi ...... lation in leukemia cell lines.

@ast

A tandem CD19/CD20 CAR lentivi ...... lation in leukemia cell lines.

@en

P1433

Q33692070-620AD006-48C1-4C58-A28B-C1B4C6E75A95

P1476

Q33692070-2A902CE7-19E0-4FD3-B125-F03E578309FE

P2093

Q33692070-1BF290F4-D4DE-41E1-B7E5-5A49A426CC12

Q33692070-70E6192C-9EDA-4DBA-B4B2-FF490B5343F0

Q33692070-814E9EA2-A3D5-41E8-8758-E15C60783077

Q33692070-8890021E-9E64-49E1-9DF0-9A132AC74D4A

Q33692070-928AAE16-6DF1-406B-A815-6798BFDAC69D

Q33692070-94652E5E-4D88-4004-9118-24DE5625F13F

Q33692070-D291D4B2-30B3-43D2-B3A8-00F4CF13B178

Q33692070-F7062DD6-774A-420D-A1BC-66003CCC97CD

Q33692070-FF334289-F576-4D2B-A50B-FA83D665B7C0

P2860

Q33692070-003FE03A-51F9-4233-B0E1-45EF245A52A3

Q33692070-03A36081-0D73-4849-813F-D215D630699D

Q33692070-0768F45B-7CA9-438E-BB93-E0B288A74492

Q33692070-12A924BC-6824-4077-8D8C-92E8A1E8A0D4

Q33692070-16D83E2E-DF21-411B-A88A-D2CE0914B41E

Q33692070-2AC6666C-AA33-4863-9004-975F4410CA00

Q33692070-2F607491-0219-496B-8ED2-1C3B96F6D44F

Q33692070-547EB85A-AADB-485C-8D35-CB44F3C53816

Q33692070-55C3EE49-21A4-4898-85CE-B80B9A441DD8

Q33692070-561EF33D-FAFD-4814-92A6-A44FF0D5D5EB

P2888

Q33692070-6CB223EB-1DDA-493F-8545-ED538BAE8A3A

P304

Q33692070-AEA0852C-9861-4B19-AD39-E9EE9EB1CD5A

P31

Q33692070-159167F2-4FAF-4299-A3D3-57BE6BF8FF78

P356

Q33692070-EEA6341E-6095-41D4-B321-1F001DB36966

P478

Q33692070-9040DD5D-73AE-465D-852C-88ABA8EEB8FD

P577

Q33692070-42C98D10-B4CC-4C28-8051-81B40AD059EC

P6179

Q33692070-808D49C0-F01A-4665-9BB8-A90DED4CFBBE

P698

Q33692070-D4A8B18D-3C4D-4B61-9992-5B9B393F6B8C

P921

Q33692070-1A5EC1F2-AA0C-4AF9-B81A-F222751DE086

P932

Q33692070-0F2E2A25-E6BE-45F4-B474-6BA63C7C23EA

P356

S40425-017-0246-1

P1433

Journal for Immunotherapy of Cancer

P1476

A tandem CD19/CD20 CAR lentivi ...... lation in leukemia cell lines.

@en

P2093

Andrew Kaiser

http://www.w3.org/2001/XMLSchema#string

Boro Dropulic

http://www.w3.org/2001/XMLSchema#string

Darong Wu

http://www.w3.org/2001/XMLSchema#string

Dina Schneider

http://www.w3.org/2001/XMLSchema#string

Rimas J Orentas

http://www.w3.org/2001/XMLSchema#string

Sarah Schmitz

http://www.w3.org/2001/XMLSchema#string

Volker Nӧlle

http://www.w3.org/2001/XMLSchema#string

Waleed Haso

http://www.w3.org/2001/XMLSchema#string

Ying Xiong

http://www.w3.org/2001/XMLSchema#string

P2860

Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia

CD19 chimeric antigen receptor (CD19 CAR)-redirected adoptive T-cell immunotherapy for the treatment of relapsed or refractory B-cell Non-Hodgkin's Lymphomas

CD19 is a major B cell receptor-independent activator of MYC-driven B-lymphomagenesis

Chimeric antigen receptor-modified T cells for acute lymphoid leukemia

B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells

Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies.

The future is now: chimeric antigen receptors as new targeted therapies for childhood cancer

Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy

Noninvasive bioluminescent imaging of primary patient acute lymphoblastic leukemia: a strategy for preclinical modeling.

A c-Myc and surface CD19 signaling amplification loop promotes B cell lymphoma development and progression in mice.

P2888

s40425-017-0246-1

P304

42

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S40425-017-0246-1

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P577

2017-05-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1085366840

http://www.w3.org/2001/XMLSchema#string

P698

28515942

http://www.w3.org/2001/XMLSchema#string

P921

P932

5433150

http://www.w3.org/2001/XMLSchema#string